X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (3127) 3127
humans (3017) 3017
pseudomonas infections - complications (2500) 2500
male (1725) 1725
female (1523) 1523
adult (1136) 1136
cystic fibrosis - complications (951) 951
pseudomonas aeruginosa (850) 850
middle aged (807) 807
pseudomonas infections - drug therapy (788) 788
adolescent (676) 676
child (645) 645
abridged index medicus (602) 602
pseudomonas aeruginosa - isolation & purification (595) 595
aged (582) 582
cystic fibrosis (578) 578
anti-bacterial agents - therapeutic use (539) 539
pseudomonas infections - microbiology (501) 501
animals (469) 469
cystic fibrosis - microbiology (437) 437
microbiology (426) 426
respiratory system (401) 401
child, preschool (393) 393
infectious diseases (364) 364
infections (349) 349
pseudomonas-aeruginosa (324) 324
infant (319) 319
infection (297) 297
pseudomonas aeruginosa - drug effects (275) 275
staphylococcal infections - complications (257) 257
pediatrics (245) 245
respiratory tract infections - complications (245) 245
chronic disease (237) 237
pseudomonas infections - diagnosis (237) 237
antibiotics (233) 233
retrospective studies (233) 233
bacterial infections - complications (231) 231
immunology (209) 209
treatment outcome (209) 209
risk factors (203) 203
mice (200) 200
sputum - microbiology (194) 194
bacteria (190) 190
anti-bacterial agents - administration & dosage (189) 189
microbial sensitivity tests (184) 184
sepsis - complications (175) 175
pseudomonas infections - immunology (173) 173
surgery (172) 172
medicine, general & internal (170) 170
health aspects (166) 166
burns - complications (154) 154
young adult (154) 154
pseudomonas aeruginosa - pathogenicity (147) 147
children (146) 146
pseudomonas aeruginosa - genetics (145) 145
anti-bacterial agents - pharmacology (144) 144
pseudomonas aeruginosa - immunology (142) 142
aged, 80 and over (140) 140
infant, newborn (137) 137
time factors (135) 135
pseudomonas (134) 134
cystic fibrosis - immunology (133) 133
lung - microbiology (133) 133
pseudomonas infections - pathology (133) 133
colonization (132) 132
prospective studies (132) 132
cystic fibrosis - physiopathology (131) 131
pharmacology & pharmacy (129) 129
mortality (128) 128
drug therapy, combination (127) 127
inflammation (125) 125
cystic fibrosis - drug therapy (124) 124
pseudomonas infections - epidemiology (123) 123
bacteremia (121) 121
pseudomonas infections - etiology (121) 121
cystic-fibrosis (119) 119
disease models, animal (118) 118
respiratory tract infections - microbiology (115) 115
acute disease (113) 113
pseudomonas infections - therapy (113) 113
burkholderia infections - complications (109) 109
follow-up studies (108) 108
pneumonia (107) 107
research (107) 107
disease (106) 106
gentamicins - therapeutic use (106) 106
opportunistic infections - complications (103) 103
pneumonia - complications (103) 103
pseudomonas aeruginosa - physiology (103) 103
urinary tract infections - complications (102) 102
drug resistance, microbial (101) 101
prognosis (101) 101
epidemiology (100) 100
escherichia coli infections - complications (99) 99
care and treatment (98) 98
rats (98) 98
respiratory tract infections - drug therapy (97) 97
pseudomonas infections - prevention & control (96) 96
sepsis (96) 96
administration, inhalation (95) 95
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2835) 2835
Japanese (115) 115
Spanish (91) 91
French (82) 82
German (59) 59
Russian (51) 51
Chinese (45) 45
Polish (27) 27
Italian (25) 25
Romanian (6) 6
Turkish (6) 6
Portuguese (5) 5
Czech (3) 3
Danish (3) 3
Dutch (3) 3
Hebrew (3) 3
Finnish (2) 2
Hungarian (2) 2
Slovak (2) 2
Bulgarian (1) 1
Serbian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
American journal of respiratory and critical care medicine, ISSN 1073-449X, 2014, Volume 190, Issue 2, pp. 175 - 184
Rationale: Ivacaftor is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator recently approved for patients with CF age 6 and older with... 
PH | Cystic fibrosis | Pseudomonas aeruginosa | Ivacaftor | CFTR modulator | LUNG-FUNCTION | ivacaftor | MUCIN SECRETION | ADRENERGIC SWEAT SECRETION | MUCOCILIARY CLEARANCE | INTESTINAL PH | CHILDREN | RESPIRATORY SYSTEM | cystic fibrosis | PSEUDOMONAS-AERUGINOSA | INFLAMMATION | DISEASE | QUESTIONNAIRE | CRITICAL CARE MEDICINE | Sputum - microbiology | Lung - microbiology | Pseudomonas aeruginosa - isolation & purification | Follow-Up Studies | Forced Expiratory Volume - drug effects | Sweat - drug effects | Humans | Microbiota - drug effects | Respiratory System Agents - therapeutic use | Hospitalization - statistics & numerical data | Male | Aminophenols - therapeutic use | Quinolones - pharmacology | Aminophenols - pharmacology | Mucociliary Clearance - drug effects | Pseudomonas Infections - prevention & control | Young Adult | Hydrogen-Ion Concentration - drug effects | Quinolones - therapeutic use | Adult | Female | Lung - metabolism | Child | Biomarkers - metabolism | Respiratory System Agents - pharmacology | Cystic Fibrosis - metabolism | Cystic Fibrosis - microbiology | Pseudomonas Infections - complications | Pseudomonas Infections - diagnosis | Treatment Outcome | Lung - physiopathology | Genetic Markers | Sputum - metabolism | Cystic Fibrosis - genetics | Intestine, Small - drug effects | Lung - drug effects | Adolescent | Cystic Fibrosis Transmembrane Conductance Regulator - genetics | Intestine, Small - metabolism | Mutation | Cystic Fibrosis - drug therapy | Sweat - metabolism | Index Medicus | Abridged Index Medicus | Original
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 5/2006, Volume 103, Issue 22, pp. 8487 - 8492
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 09/2016, Volume 63, Issue 6, pp. 754 - 762
Background. The global emergence of carbapenem-resistant Enterobacteriaceae highlights the urgent need to reduce carbapenem dependence. The phase 3 RECAPTURE... 
acute pyelonephritis | ceftazidime-avibactam | complicated urinary tract infection | INFECTIOUS DISEASES | INITIAL ANTIBIOTIC-THERAPY | ANTIMICROBIAL THERAPY | MICROBIOLOGY | IMMUNOLOGY | INTRAABDOMINAL INFECTION | CARBAPENEM-RESISTANT ENTEROBACTERIACEAE | TREATMENT OPTIONS | BACTERICIDAL ACTIVITY | PSEUDOMONAS-AERUGINOSA | LACTAMASE-PRODUCING ENTEROBACTERIACEAE | SPECTRUM BETA-LACTAMASES | KLEBSIELLA-PNEUMONIAE | Doripenem | Azabicyclo Compounds - administration & dosage | Carbapenems - administration & dosage | Humans | Middle Aged | Male | Pyelonephritis - complications | Urinary Tract Infections - complications | Urinary Tract Infections - drug therapy | Carbapenems - adverse effects | Anti-Bacterial Agents - therapeutic use | Carbapenems - therapeutic use | Ceftazidime - administration & dosage | Adult | Azabicyclo Compounds - therapeutic use | Female | Aged | Anti-Bacterial Agents - adverse effects | Ceftazidime - adverse effects | Pyelonephritis - drug therapy | Anti-Bacterial Agents - administration & dosage | Ceftazidime - therapeutic use | Drug Combinations | Azabicyclo Compounds - adverse effects | Care and treatment | Usage | Pyelonephritis | Clinical trials | Urinary tract infections | Influence | Dosage and administration | Ceftazidime | Antibiotics | Drug resistance | Drug therapy | CRE bacteria | Urinary tract diseases | Index Medicus | and Commentaries
Journal Article
Journal Article
Journal Article